Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.14
43.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hubei Jumpcan Pharmaceutical Co Ltd
Total Current Liabilities
Hubei Jumpcan Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
|
Total Current Liabilities
¥4.3B
|
CAGR 3-Years
30%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Current Liabilities
¥6.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Current Liabilities
¥2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
26%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Current Liabilities
¥4.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Current Liabilities
¥13.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Current Liabilities
¥1.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hubei Jumpcan Pharmaceutical Co Ltd
Glance View
In the bustling landscape of China's pharmaceutical industry, Hubei Jumpcan Pharmaceutical Co Ltd stands as a key player, weaving together tradition and modernity. Founded in 1951, this company has curated a journey of evolution—from its roots in the rich tapestry of traditional Chinese medicine to its current standing as a significant contributor to the healthcare sector. Core to Jumpcan's operation is its production and distribution of a diverse array of pharmaceutical products that span across various therapeutic areas, including digestive health, dermatology, and respiratory care. With an adept focus on over-the-counter medications and prescription drugs, Jumpcan effectively meets the health needs of a broad demographic, leveraging both the enduring appeal of traditional remedies and the growing demand for contemporary medical solutions. The business prowess of Jumpcan is deeply entwined with its strategy of innovation and adherence to quality standards, ensuring its pharmaceutical offerings are not only effective but also safe for consumption. Anchored in robust R&D initiatives, the company continues to enhance its product line, incorporating advanced technology and scientific research to produce medicines that align with global quality benchmarks. Furthermore, Jumpcan thrives on an extensive distribution network that spans across China, ensuring widespread accessibility of its products. By maintaining a keen understanding of the market dynamics and consumer preferences, Jumpcan artfully aligns its operations to capitalize on both domestic and international opportunities, thus solidifying its financial standing and perpetuating its growth within the dynamic corridors of the pharmaceutical industry.
See Also
What is Hubei Jumpcan Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
4.3B
CNY
Based on the financial report for Sep 30, 2024, Hubei Jumpcan Pharmaceutical Co Ltd's Total Current Liabilities amounts to 4.3B CNY.
What is Hubei Jumpcan Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
19%
Over the last year, the Total Current Liabilities growth was 11%. The average annual Total Current Liabilities growth rates for Hubei Jumpcan Pharmaceutical Co Ltd have been 30% over the past three years , 17% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet